title: “AI Agents for Biotech Research: Automating Drug Discovery Workflows”
meta_description: “How AI agents automate biotech R&D. Real examples from Insilico Medicine, AstraZeneca, and Benchling. Tools and workflows for drug discovery.”
primary_keyword: “AI agents for biotech research”
secondary_keywords:
– “agentic AI for biotech R&D”
– “AI drug discovery automation”
– “AI-assisted drug discovery”
suggested_tags:
– “Biotech AI”
– “Drug Discovery”
– “AI Automation”
– “R&D Efficiency”
AI Agents for Biotech Research: Automating Drug Discovery Workflows
I’ve been in biotech for 15 years. In that time, I’ve watched the drug discovery timeline inch down marginally—from 4.5 years to maybe 4 years if you were lucky. Incremental progress. Thousands of companies, billions of dollars, and we were still grinding through the same bottleneck: the early-stage discovery phase is slow.
In the last 18 months, that’s changed.
Agentic AI—autonomous systems that propose experiments, design follow-up studies, and iterate in real time—is compressing what used to take a year into what now takes weeks. This isn’t hype. It’s happening at AstraZeneca, which has 90% of its small molecule discovery pipeline AI-assisted. It’s happening at Eli Lilly, which launched TuneLab to give external biotech companies access to proprietary AI discovery models. It’s happening at Insilico Medicine, which nominated a preclinical drug candidate in 12–18 months versus the industry average of 4.5 years.
This shift is significant enough to matter to your startup’s unit economics, your timeline to clinical validation, and your probability of success.
The R&D Bottleneck in Biotech
To understand why agentic AI matters so much, you first need to understand where the time actually goes.
Drug discovery splits into phases:
- Target discovery and validation (1–2 years): Identify the disease mechanism and which protein/target to hit.
- Lead discovery (2–3 years): Find molecules that bind the target and show the right properties.
- Lead optimization (1–2 years): Improve potency, selectivity, and pharmacokinetics.
- Preclinical candidate nomination (0.5–1 year): Select the best compound for regulatory submission.
- IND-enabling studies (1–2 years): Toxicology, manufacturing, formulation work required for FDA approval to test in humans.
Steps 2–4 are the killer. They’re where you synthesize and test thousands of molecules. Most fail. The process is serial: you design compound A, synthesize it (2 weeks), test it (1 week), get results (1 week), then repeat. One cycle per month per series. Some programs run 20+ cycles.
That’s the bottleneck: the length of each design-synthesis-test cycle and the number of cycles needed to find a suitable lead.
Traditional process:
– Medicinal chemist makes a hypothesis about a structure modification.
– Synthesis team agrees it’s feasible.
– Chemistry synthesis lab takes 2–4 weeks to make the compound.
– Biology lab takes 1–2 weeks to run the assay.
– Results come back. Decision on next cycle.
The human in the loop—the medicinal chemist—has to review data, form hypotheses, and decide what to make next. That chemist has maybe 10–20 active projects. They batch decisions. Even with the best teams, one cycle every 4 weeks is standard.
Agentic AI attacks this bottleneck at multiple levels:
1. Hypothesis generation: Instead of one chemist proposing structures, an AI agent proposes dozens of candidates simultaneously.
2. Parallel exploration: The agent can prioritize hundreds of molecules for synthesis, balancing novelty, synthesizability, and predicted potency.
3. Real-time iteration: As data comes back, the agent immediately refines the search space instead of waiting for batch review.
4. Decision leverage: Chemists spend their time on hard problems (novel scaffolds, difficult chemistry) and let the agent handle routine structure optimization.
The result: Lead discovery that took 2–3 years now takes 4–8 months.
That’s not a 20% productivity gain. That’s a 70–80% time compression. For a biotech company trying to get to Phase 1, that’s 18 months faster. For a company trying to fund another discovery program, that’s the difference between 3 programs or 5 programs in the same calendar window.
What AI Agents Can Actually Do in a Lab
Let me be specific about what agents are handling now versus what still requires humans.
What Agents Do Well
Literature and data mining: Agents can search scientific literature, extract relevant papers, summarize findings, and identify known binding modes or off-target liabilities for a given target. This used to take a chemist 1–2 weeks per new target. An agent does it in hours.
Example workflow:
– Goal: “Identify known ligands and binding modes for the EGFR L858R mutant.”
– Agent:
– Queries PubMed and ChemBL for EGFR inhibitors.
– Retrieves crystal structures from PDB.
– Extracts SAR (structure–activity relationship) patterns.
– Identifies selectivity challenges (kinase cross-reactivity).
– Summarizes gaps in the literature.
– Output: Comprehensive 2-hour analysis. A medicinal chemist would need a week.
Structure generation and optimization: Agents can propose novel molecular structures based on a target, known actives, and design rules.
Modern systems use:
– Generative chemistry models (trained on millions of known compounds and their properties): These propose novel structures.
– Molecular docking and scoring: Predict binding affinity and off-target binding.
– Property prediction: Estimate solubility, metabolic stability, toxicity flags, synthetic accessibility.
The agent ranks proposals by multiple criteria (potency, novelty, synthesizability, safety) and presents a ranked list to the chemist.
Example: Insilico Medicine’s Pharma.AI nominated 20 preclinical candidates from 2021–2024, with an average timeline of 12–18 months per program and only 60–200 molecules synthesized and tested per program. That’s 1/10 the typical number of molecules to reach a preclinical candidate.
Experimental design and prioritization: Given a hypothesis and a set of molecules, agents can design the next experiments (which assays to run, what variants to test, which compounds to prioritize) based on previous data.
This is where the real leverage emerges. Instead of a chemist reviewing 100 data points and deciding “let’s test 5 of these,” an agent can systematically evaluate all 100, identify the most informative next steps, and recommend 20 compounds for the next round.
Synthesis feasibility assessment: Agents can predict how hard a molecule is to synthesize, whether the chemistry is known, whether new chemistry development is required, and rough timelines.
This is valuable because it prevents the agent from proposing structures that are theoretically good but practically impossible to make.
What Still Requires Humans
High-stakes novelty decisions: An agent can propose a novel scaffold based on similarity to known actives. But deciding “is this truly novel, or are we reinventing the wheel?” requires judgment. Medicinal chemists with domain expertise still make that call.
Synthesis execution: The agent recommends what to make. Chemists and technicians still make it. Synthesis hasn’t been automated end-to-end in most labs (though some groups are working on that).
Assay interpretation and anomalies: An agent can run assays and flag anomalies (“this compound is potent but the solubility is terrible”). But interpreting what that means for the program (“do we pursue a prodrug, or pivot to a different scaffold?”) is a human decision.
Target selection and validation: An agent can help with the decision (literature analysis, mechanism of action, off-target risk), but the choice to commit a program to a target still involves senior scientists, clinicians, and business judgment.
Regulatory and clinical decisions: Should this candidate go to IND-enabling studies? What’s the risk of a certain toxicity finding? Agents inform these decisions. Humans make them.
Experimental troubleshooting: If an assay gives weird results, or a synthesis fails unexpectedly, humans debug. Agents can suggest hypotheses, but execution and judgment are human-driven.
The pattern: Agents handle high-volume, routine, decision-heavy work. Humans handle novel, ambiguous, high-stakes decisions.
This is the partnership model that’s winning in 2026.
[INTERNAL LINK: Agentic AI Explained: How Autonomous AI Systems Actually Work]
Current Tools and Platforms
Here’s what’s available now, categorized by approach:
Integrated Platforms (All-in-One AI Discovery)
Insilico Medicine – Pharma.AI
- What it does: End-to-end drug discovery automation. Literature analysis → target identification → compound generation → property prediction → lead optimization.
- Specific capabilities: Generative chemistry engine, multimodal AI (integrates protein structure, genetics, transcriptomics), multi-target optimization.
- Real results: 12–18 months per preclinical candidate (vs. 4.5 years industry average). 60–200 molecules per program (vs. 1000+ typical).
- Cost: Not publicly listed. Enterprise contracts negotiated with pharma.
- Maturity: Production. Multiple compounds in clinical development.
Eli Lilly – TuneLab (via Benchling)
- What it does: Access to Lilly’s proprietary AI/ML models for drug discovery, integrated into Benchling’s lab management platform.
- Specific capabilities: Antibody design, small molecule property prediction, PK/PD modeling trained on Lilly’s proprietary data.
- Launch: September 2025. “Drug discovery as a service” for external biotech.
- Availability: Available to biotech companies using Benchling.
- Cost: Subscription model (not publicly priced). Lower barrier than building models from scratch.
AstraZeneca’s Internal Platform
- Approach: Not publicly commercialized, but extensively documented.
- What it does: AI-assisted small molecule design, biology prediction, chemistry optimization.
- Scale: >90% of AstraZeneca’s small molecule pipeline is AI-assisted. 70% of chemistry projects use AI for compound selection.
- Key insight: AstraZeneca didn’t build one mega-platform. They built modular AI agents for specific tasks (property prediction, novelty scoring, synthesis planning) and integrated them into existing workflows.
This modular approach is worth copying. Don’t try to automate all of drug discovery with one tool. Automate specific high-volume decisions.
Specialized AI Tools (Component-Based)
Benchling AI
- What it does: Agentic AI directly in Benchling’s R&D OS. Components include “Ask” (literature search), “Compose” (protocol generation), “Deep Research” (analysis), “Data Entry” (extraction).
- Current adoption: 500+ biotech companies using Benchling AI.
- Integration: Sits inside your existing lab workflows (notebooks, inventory, results tracking).
- Cost: Subscription, tiered by usage.
- Maturity: Generally available as of 2025.
Recursion – Recursion OS + AI Agents
- What it does: AI-guided high-throughput screening. The agent designs what to test, predicts outcomes, and prioritizes molecules based on biology data.
- Approach: Combines wet-lab automation (cell imaging) with AI decision-making.
- Scale: Recursion is using this internally for programs; they’re beginning to license capability.
DeepMind’s AlphaFold and AlphaFold3
- What it does: Protein structure prediction and design. Not a drug discovery platform per se, but a critical component of most modern discovery workflows.
- Real impact: Enables structure-based drug design. Removes the constraint of “we don’t have the protein structure, so we’ll have to use traditional SAR.”
- Cost: Free online tool (AlphaFold2). Enterprise licensing available for AlphaFold3.
- In practice: Most modern drug discovery programs incorporate AlphaFold-generated structures into their compound design loop.
Schrödinger (Benchling’s minority stake)
- What it does: Molecular simulation, property prediction, and chemistry planning.
- Use case: Predicting ADMET properties, off-target binding, synthesizability.
- Integration: Available standalone or integrated into Benchling workflows.
Nexus Informatics – Molecular AI
- What it does: Generative chemistry and lead optimization. Proposes novel structures and ranks them.
- Real use case: Small biotech companies often use this for lead series expansion.
Build-Your-Own Components
If you want to build a custom agentic discovery system, you can assemble open-source and API components:
- Structure generation: DeepMind’s ProteinMPNN (protein design), or fine-tuned models on ChemBL data.
- Binding prediction: AlphaFold3, RoseTTAFold, or Rosetta (structure prediction). ESMFold for fast predictions.
- Property prediction: Open-source models trained on public data, or proprietary models from Schrödinger.
- Orchestration: LangGraph, CrewAI, or custom Python.
- Database integrations: Connect to ChemBL, PubChem, UniProt, PDB via APIs.
- Execution: Run on HPC clusters (AWS, GCP) or on-premise.
Cost: Largely free or pay-per-compute. Data infrastructure is the real cost. Chemistry expertise is the constraint.
This approach is viable for large pharma (which has in-house chemistry teams) and well-funded biotech (which can hire or partner for chemistry expertise). It’s harder for early-stage companies without chemistry depth.
Real Case Studies
Insilico Medicine: 12–18 Months Per Candidate
In December 2024, Insilico Medicine published results showing:
– Nominated 20 preclinical candidates from 2021–2024.
– Average timeline per program: 12–18 months from initiation to preclinical candidate selection.
– Average molecules synthesized per program: 60–200.
Compare to industry benchmarks:
– Timeline: 4.5 years (vs. Insilico’s 18 months = 60% faster)
– Synthesis load: 1,000–3,000 molecules (vs. Insilico’s 60–200 = 80–90% fewer)
The method: Multi-agent system combining generative chemistry, protein structure prediction, and iterative feedback from wet-lab results.
A 12-to-18-month timeline matters because:
1. For a startup: That’s the difference between validating a target and running out of money versus reaching preclinical candidate and raising a Series A.
2. For a larger pharma: That’s bandwidth to run 3–4 discovery programs in parallel instead of 1–2.
3. For investors: It’s a signal of technical risk mitigation. A company that can move fast has lower probability of failure.
AstraZeneca: 90% Pipeline Coverage
AstraZeneca publicly reported (2025) that over 90% of its small molecule discovery pipeline is now AI-assisted. This includes:
– Compound design: AI proposes structures.
– Property prediction: AI estimates ADMET, toxicity, selectivity.
– Synthesis planning: AI prioritizes molecules by synthesizability.
The company also uses AI to optimize which molecules get made (70% of chemistry projects use AI for compound selection).
The outcome: Faster iteration, fewer dead-end syntheses, and higher hit rates (proportion of molecules with desired activity).
AstraZeneca’s approach is instructive because it’s modular. They didn’t replace chemists with AI. They replaced decision processes with AI:
– “Which 20 compounds should the chemistry team make next?” → Answered by AI, using binding predictions, novelty scoring, and synthesis feasibility.
– “Should we pursue this series further?” → Answered by humans, but informed by AI-generated SAR analysis.
Benchling: 500+ Biotech Companies Using AI Agents
Benchling’s 2026 Biotech AI Report shows:
– 500+ biotech companies now use Benchling AI.
– Top use cases: Literature review (76% adoption), protein structure prediction (71%), scientific reporting (66%), target identification (58%).
– Impact: 50% of biotech report faster time-to-target. 56% expect cost reductions within two years.
The volume and speed of adoption suggest that the infrastructure for agentic biotech is now plug-and-play. Companies don’t need to build from scratch. They’re adopting existing platforms.
This is the inflection point. When enough companies use the same platform, best practices emerge, talent flows to where the tools are, and that becomes the standard.
How to Get Started: A Practical Roadmap
If you’re building a biotech company or running discovery at an established firm, here’s how to incorporate agentic AI:
Phase 1: Audit Your Bottlenecks (Weeks 1–4)
Don’t implement AI everywhere. Identify the specific process that’s slowing you down:
– Is it literature review and target validation? (High-volume information gathering)
– Is it structure design and property prediction? (High-volume decision-making)
– Is it experimental prioritization? (High-stakes decision-making based on data)
Track actual time spent. Talk to your scientists. “Where are you spending 50% of your time that could be automated?”
Phase 2: Pick a Tool (Weeks 5–8)
If you’re using Benchling: Just turn on Benchling AI agents. Start with literature review and protocol generation. Then expand to deep research and property prediction.
Cost: Included with Benchling subscription (usually $1K–5K/month depending on scale).
If you want Lilly’s proprietary models: Get access to TuneLab via Benchling (recent partnership).
If you have unique chemistry: Consider a custom platform:
– Partner with a discovery CRO that uses AI (e.g., Nimbus Discovery, which combines AI agents with wet lab services).
– Build using LangGraph/CrewAI + open-source models + your data.
Cost: Custom platform is expensive. Budget $50K–200K+ to get a working MVP.
Phase 3: Run a Pilot (Months 2–6)
Pick one specific task: “Use the AI agent to propose structures for our lead series.” Run it in parallel with your current process. Don’t replace the human process yet.
Metrics to track:
– Time savings: How much faster is the AI proposal vs. manual design?
– Quality: Do the AI proposals match human creativity or exceed it?
– Adoption: Do your scientists actually use the tool, or do they ignore it?
Poor adoption often means the tool doesn’t integrate well with existing workflows. Fix the integration first; then assess quality.
Phase 4: Expand and Optimize (Months 6–12)
If the pilot works, expand to related tasks:
– If you automated structure design, automate synthesis planning next.
– If you automated literature review, automate protocol generation next.
Build dashboards to track:
– Time per cycle (design-synthesize-test loop speed)
– Number of active compounds in the pipeline
– Hit rate (% of compounds with desired activity)
– Cost per preclinical candidate
Compare before and after.
Phase 5: Integrate Into Core Workflows (Months 12+)
At this point, the agent is no longer an “AI tool”—it’s part of your R&D process. Build the organizational structure to support it:
– AI chemist role: Someone who understands both the AI system and the chemistry, responsible for prompt engineering and validation.
– Data infrastructure: Ensure clean, structured data flowing from your LIMS to the AI system.
– Feedback loop: Close the loop: AI proposes → lab executes → results feed back into AI → next proposal improves.
This feedback loop is critical. AI agents improve when they see real lab results. The first proposals might be mediocre. By cycle 50, they’re often excellent.
Limitations: What Agentic AI Can’t Do Yet
Be realistic about what’s not working:
1. Truly Novel Targets
Agentic AI excels at optimizing within a known target space. But identifying a completely new target (one with no known ligands, no prior art) is still largely human work. The agent can help (literature analysis, mechanistic reasoning), but the breakthrough insight is human-driven.
2. Complex Polypharmacology
If you need a compound that hits two targets simultaneously (a common strategy), agentic systems can help but struggle with the tradeoffs. Humans still make these calls.
3. Uncertain Assay Results
If your assay is noisy or poorly characterized, the agent will hallucinate interpretations. Agentic systems need clean, high-confidence feedback. Noisy biology breaks them.
4. Regulatory and Clinical Judgment
“Is a 10% incidence of a specific liver enzyme elevation acceptable in the IND?” That’s a human question. An agent can gather data and precedent, but humans decide.
5. Rare or Exotic Chemistry
If your program requires novel synthetic chemistry not seen in the literature, agents struggle. They’re trained on known chemistry. New chemistry is human territory.
What’s Changing in 2026–2027
Multimodal integration: Agents will better integrate multiple data types—sequences, structures, images, raw experimental data—into a unified decision framework.
Closed-loop automation: Some biotech companies are moving toward fully automated synthesis + testing + interpretation + next-hypothesis generation. This is early but it’s coming.
Proprietary data moats: Companies with large internal datasets (like Lilly, AstraZeneca, Genentech) can fine-tune models on their data and get better performance than generic platforms. This creates a sustainable competitive advantage.
Shift to earlier stages: Right now, agents help with small molecule discovery. They’re moving into target discovery and earlier validation. Expect agents to help with clinical trial design and optimization next.
Integration with wet-lab automation: Robotic high-throughput screening + AI agent decision-making is the endgame. Not there yet, but several companies (including Recursion) are building this.
The Bottom Line
Agentic AI is no longer theoretical in biotech. It’s production. If you’re starting a discovery program in 2026, you should be assuming AI-assisted workflows as your baseline. The question isn’t “should we use AI?” but “which tasks should humans focus on because they’re less suited for AI?”
The 18-month preclinical candidate timeline is real. It’s achievable with current technology. Companies doing it now have a structural advantage: faster learning cycles, faster iteration, and faster path to clinical validation.
If you’re not already incorporating agentic systems into your discovery process, you should start. The window for adopting this tech while it’s still a competitive advantage is narrow. By 2027, it’ll be table stakes.
Key Takeaways
- The R&D bottleneck is real: Lead discovery is slow. Agentic AI compresses that phase from 2–3 years to 4–8 months.
- Agents handle routine, high-volume decisions. Humans make novel, high-stakes calls. Partnership wins.
- Production systems exist now: Insilico Medicine, AstraZeneca, Benchling—these are shipping, not research.
- Start with your biggest bottleneck, not with hype. Audit your process. Pick one task to automate.
- Feedback loops are everything. AI improves when it sees real lab results.
- Proprietary data matters. Companies with large internal datasets can fine-tune models and pull ahead.
The companies that nail the human-AI partnership in biotech discovery will define the next decade of pharmaceutical innovation.
Following AI developments in biotech and deep tech? Subscribe to Accelerated, Grey Area Labs’ newsletter. We interview founders, analyze data, and cut through marketing noise.
[Subscribe to Accelerated →]